"ファイザー" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonPfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss - CNBC
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss CNBC
- Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal NBC News
- Lyme disease vaccine shows 70 percent efficacy, Pfizer says The Washington Post
- Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial WSJ
- Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle statnews.com
- Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push Fierce Biotech
- Pfizer Says Long-Awaited Lyme Vaccine Was Effective in Study Bloomberg.com
- Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial MarketWatch
- Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Yahoo Finance
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC - Business Wire
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC Business Wire
Pfizer says long-awaited Lyme vaccine was effective in study - The Detroit News
Pfizer says long-awaited Lyme vaccine was effective in study The Detroit News
Pfizer and Valneva Report Vaccine Efficacy Data for Their Lyme Disease Candidate - Contagion Live
Pfizer and Valneva Report Vaccine Efficacy Data for Their Lyme Disease Candidate Contagion Live
Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal - Reuters
Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal Reuters
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design - BioSpace
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design BioSpace
Lyme disease vaccine 70 percent effective: Pfizer - The Hill
Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss - pharmaphorum
Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss pharmaphorum
No Lyme vaccine exists; Pfizer candidate topped 70% efficacy - Stock Titan
No Lyme vaccine exists; Pfizer candidate topped 70% efficacy Stock Titan
Pfizer, Valneva to file for approval of Lyme disease jab despite key study falling short - FirstW...
Pfizer, Valneva to file for approval of Lyme disease jab despite key study falling short FirstWord Pharma
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint - BioSpace
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint BioSpace
Pfizer’s Lyme vaccine results set up tricky regulatory path - statnews.com
Pfizer’s Lyme vaccine results set up tricky regulatory path statnews.com
Pharmalittle: We're reading about Iran war's impact on pharma supply chain, a Pfizer Lyme vaccine...
Pharmalittle: We're reading about Iran war's impact on pharma supply chain, a Pfizer Lyme vaccine, and more statnews.com
PFE Stock Quote Price and Forecast - CNN
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate (PFE:NYSE) - Seeking Alpha
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate (PFE:NYSE) Seeking Alpha
Lyme disease vaccine shows strong results in clinical trial - Euronews.com
Lyme disease vaccine shows strong results in clinical trial Euronews.com
Pfizer Among World’s Most Ethical Companies for 5th Straight Year - Pfizer
Pfizer Among World’s Most Ethical Companies for 5th Straight Year Pfizer
Pfizer Lyme vaccine shows 70% efficacy, misses trial goal - Yahoo
Pfizer Lyme vaccine shows 70% efficacy, misses trial goal Yahoo
Strong efficacy in Phase III for Pfizer/Valneva’s Lyme disease vaccine - The Pharma Letter
Strong efficacy in Phase III for Pfizer/Valneva’s Lyme disease vaccine The Pharma Letter
Pfizer adds to Seagen scrap heap with another early cancer candidate cull - Fierce Biotech
Pfizer adds to Seagen scrap heap with another early cancer candidate cull Fierce Biotech
Pfizer and Valneva announce Lyme disease vaccine candidate shows strong efficacy in Phase III tri...
Pfizer and Valneva announce Lyme disease vaccine candidate shows strong efficacy in Phase III trial PharmaLive
Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results - Yahoo Finance
Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results Yahoo Finance
Pfizer touts atirmociclib success | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Pfizer touts atirmociclib success | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Goodman Financial Corp Purchases 137,772 Shares of Pfizer Inc. $PFE - MarketBeat
Goodman Financial Corp Purchases 137,772 Shares of Pfizer Inc. $PFE MarketBeat
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win - Fierce Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win Fierce Pharma
Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook - Yahoo Finance
Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook Yahoo Finance
Pfizer (PFE) Reports Positive Phase 3 Results for Lyme Disease V - GuruFocus
Pfizer (PFE) Reports Positive Phase 3 Results for Lyme Disease V GuruFocus
Nordea Investment Management AB Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Nordea Investment Management AB Cuts Stock Holdings in Pfizer Inc. $PFE MarketBeat
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success - TipRanks
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success TipRanks
Wealth Enhancement Advisory Services LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
Wealth Enhancement Advisory Services LLC Boosts Stake in Pfizer Inc. $PFE MarketBeat
Pfizer and Valneva Aim for Lyme Disease Vaccine Approval Despite Mixed Trial Outcome - StockInves...
Pfizer and Valneva Aim for Lyme Disease Vaccine Approval Despite Mixed Trial Outcome StockInvest.us
Pfizer, Valneva Lyme disease vaccine shows 73% efficacy in trial - Investing.com
Pfizer, Valneva Lyme disease vaccine shows 73% efficacy in trial Investing.com
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer - Clinical Trials Arena
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer Clinical Trials Arena
Pfizer (PFE) Reports Promising Phase 3 Results for Lyme Disease Vaccine - GuruFocus
Pfizer (PFE) Reports Promising Phase 3 Results for Lyme Disease Vaccine GuruFocus
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive - Benzinga
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive Benzinga
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
Pfizer vs Moderna: Which Pharma Stock Has More Upside? The Motley Fool
The Lipitor Warning for GLP-1 Drugmakers - The Medicine Maker
The Lipitor Warning for GLP-1 Drugmakers The Medicine Maker
Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels - Yahoo Finance
Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels Yahoo Finance
Pfizer's hotly tipped breast cancer prospect records phase 2 win - Fierce Biotech
Pfizer's hotly tipped breast cancer prospect records phase 2 win Fierce Biotech
Pfizer, Valneva Report Strong Phase 3 Results for Lyme Disease Vaccine Candidate - finchannel
Pfizer, Valneva Report Strong Phase 3 Results for Lyme Disease Vaccine Candidate finchannel
Pfizer: I'm Still Expecting A Massive Rebound (NYSE:PFE) - Seeking Alpha
Pfizer: I'm Still Expecting A Massive Rebound (NYSE:PFE) Seeking Alpha
New Lyme Disease Vaccine Shows Promise in Major Clinical Trial - Fine Day 102.3
New Lyme Disease Vaccine Shows Promise in Major Clinical Trial Fine Day 102.3
Pfizer's (PFE.US) Lyme disease vaccine shows 73% efficacy, but trial results remain uncertain. - ...
Pfizer's (PFE.US) Lyme disease vaccine shows 73% efficacy, but trial results remain uncertain. 富途牛牛
Pfizer’s Ibrance successor moves forward with new study data - BioPharma Dive
Pfizer’s Ibrance successor moves forward with new study data BioPharma Dive
Should You Avoid Pfizer? Here's the Key Risk to Watch - The Motley Fool
Should You Avoid Pfizer? Here's the Key Risk to Watch The Motley Fool
Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now - The Globe and Mail
Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now The Globe and Mail
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmocicli...
Pfizer CEO Albert Bourla collects $27.6M in 2025 pay following Metsera, MFN deals - Fierce Pharma
Pfizer CEO Albert Bourla collects $27.6M in 2025 pay following Metsera, MFN deals Fierce Pharma
Pfizer warns shareholders against below-market mini-tender offer - Investing.com
Pfizer warns shareholders against below-market mini-tender offer Investing.com
Pfizer and French Partner to Seek Approval for Lyme Disease Vaccine After Late-stage Trial - 富途...
Pfizer and French Partner to Seek Approval for Lyme Disease Vaccine After Late-stage Trial 富途牛牛
Pfizer Inc. stock underperforms Friday when compared to competitors - MarketWatch
Pfizer Inc. stock underperforms Friday when compared to competitors MarketWatch
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win - Endpoints News
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win Endpoints News
Pfizer (PFE) & Valneva report Phase 3 Lyme vaccine data - grafa.com
Pfizer (PFE) & Valneva report Phase 3 Lyme vaccine data grafa.com
Pfizer Recommends Shareholders Reject Tutanota Mini-Tender Offer - marketscreener.com
Pfizer Recommends Shareholders Reject Tutanota Mini-Tender Offer marketscreener.com
Pfizer recommends shareholders reject the mini-tender offer by Tutanota - marketscreener.com
Pfizer recommends shareholders reject the mini-tender offer by Tutanota marketscreener.com
Accelerating Innovation: Pfizer’s 2025 AI Festival - Pfizer
Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout - ChartMill
Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout ChartMill
Pfizer Recommends Shareholders Reject The Mini-Tender Offer By Tutanota - TradingView
Pfizer Recommends Shareholders Reject The Mini-Tender Offer By Tutanota TradingView
AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE MarketBeat
Hudson Bay Capital Management LP Has $3.57 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Hudson Bay Capital Management LP Has $3.57 Million Stock Holdings in Pfizer Inc. $PFE MarketBeat
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? The Globe and Mail
Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial - Citeline News & Insights
Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial Citeline News & Insights
Pfizer and Valneva: Their Lyme Disease Vaccine Effective Over 70% - Idéal Investisseur
Pfizer and Valneva: Their Lyme Disease Vaccine Effective Over 70% Idéal Investisseur
Wilmington Savings Fund Society FSB Sells 75,143 Shares of Pfizer Inc. $PFE - MarketBeat
Wilmington Savings Fund Society FSB Sells 75,143 Shares of Pfizer Inc. $PFE MarketBeat
BCGM Wealth Management LLC Takes Position in Pfizer Inc. $PFE - MarketBeat
BCGM Wealth Management LLC Takes Position in Pfizer Inc. $PFE MarketBeat
Wilsey Asset Management Inc. Has $29.77 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Wilsey Asset Management Inc. Has $29.77 Million Stock Holdings in Pfizer Inc. $PFE MarketBeat
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - CNBC
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial CNBC
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - AOL.com
Pfizer vs Moderna: Which Pharma Stock Has More Upside? AOL.com
Pfizer, Roche Looking Beyond Simple Licensing In China Deals - Citeline News & Insights
Pfizer, Roche Looking Beyond Simple Licensing In China Deals Citeline News & Insights
Why Is Pfizer Stock Gaining Thursday? - Pfizer (NYSE:PFE) - Benzinga
Why Is Pfizer Stock Gaining Thursday? - Pfizer (NYSE:PFE) Benzinga
Pfizer (NYSE:PFE) Stock Price Down 1.6% - Should You Sell? - MarketBeat
Pfizer (NYSE:PFE) Stock Price Down 1.6% - Should You Sell? MarketBeat
Pfizer (PFE) Advises Against Accepting Tutanota's Mini-Tender Of - GuruFocus
Pfizer (PFE) Advises Against Accepting Tutanota's Mini-Tender Of GuruFocus
Swiss Life Asset Management Ltd Decreases Position in Pfizer Inc. $PFE - MarketBeat
Swiss Life Asset Management Ltd Decreases Position in Pfizer Inc. $PFE MarketBeat
CIBC Bancorp USA Inc. Invests $20.07 Million in Pfizer Inc. $PFE - MarketBeat
CIBC Bancorp USA Inc. Invests $20.07 Million in Pfizer Inc. $PFE MarketBeat
Reducing Hours to Seconds: How Pfizer Transformed Global Patient Care with Innovation and Strateg...
Reducing Hours to Seconds: How Pfizer Transformed Global Patient Care with Innovation and Strategy Strategy
Pfizer recommends shareholders reject mini-tender offer by Tutanota - TipRanks
Pfizer recommends shareholders reject mini-tender offer by Tutanota TipRanks
Achmea Investment Management B.V. Acquires 201,826 Shares of Pfizer Inc. $PFE - MarketBeat
Achmea Investment Management B.V. Acquires 201,826 Shares of Pfizer Inc. $PFE MarketBeat
CIBC Private Wealth Group LLC Sells 421,571 Shares of Pfizer Inc. $PFE - MarketBeat
CIBC Private Wealth Group LLC Sells 421,571 Shares of Pfizer Inc. $PFE MarketBeat
Pfizer (PFE) Advises Against Tutanota's Mini-Tender Offer - GuruFocus
Pfizer (PFE) Advises Against Tutanota's Mini-Tender Offer GuruFocus
Morgan Doctoral Student Selected as Pfizer Fellow Advancing Vaccine Innovation - Morgan State Uni...
Morgan Doctoral Student Selected as Pfizer Fellow Advancing Vaccine Innovation Morgan State University
President announces TrumpRx website for drugs, and pricing deal with Pfizer - NPR
President announces TrumpRx website for drugs, and pricing deal with Pfizer NPR
Drug Prices: Will the New Pfizer Deal Lower Costs for Americans? - National Academy of Medicine
Drug Prices: Will the New Pfizer Deal Lower Costs for Americans? National Academy of Medicine
Pfizer tops estimates, raises profit guidance even as sales fall - CNBC
Pfizer tops estimates, raises profit guidance even as sales fall CNBC
Captrust Financial Advisors Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Captrust Financial Advisors Cuts Stake in Pfizer Inc. $PFE MarketBeat
How Pfizer’s CEO wielded moral clarity to help his team do the impossible - Fortune
How Pfizer’s CEO wielded moral clarity to help his team do the impossible Fortune
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill - CNBC
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill CNBC
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - CNBC
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook CNBC
U.S. Pneumococcal Vaccines Market Is Going to Boom | Pfizer • Merck & Co. • GlaxoSmithKline • San...
U.S. Pneumococcal Vaccines Market Is Going to Boom | Pfizer • Merck & Co. • GlaxoSmithKline • Sanofi openPR.com
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies - BioSpace
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies BioSpace
Jain Global LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Enters into Agreement with Walgreens to Help Eligible U.S. Adults Navigate Their Healthcar...